FDA Initiates Class II Recall for ACME UNITED's Benzalkonium Chloride Wipes Due to CGMP Deviations
ACME UNITED CORPORATION has initiated a nationwide Class II recall (D-0365-2026) for its Medi-First Antiseptic Wipes containing Benzalkonium Chloride 0.13%. This voluntary action, prompted by Current Good Manufacturing Practice (CGMP) deviations, signals significant regulatory risk. Procurement and regulatory teams must assess supply chain vulnerabilities and ensure robust quality oversight for OTC drug products to mitigate business disruption and compliance exposure.
FDA Initiates Class II Recall for ACME UNITED's Benzalkonium Chloride Wipes Due to CGMP Deviations
ACME UNITED CORPORATION, based in Shelton, CT, has initiated a voluntary nationwide Class II recall (D-0365-2026) for specific lots of its Medi-First Antiseptic Wipes. This critical action, initiated on January 20, 2026, and currently ongoing, stems directly from identified Current Good Manufacturing Practice (CGMP) deviations. The affected product, an Over-The-Counter (OTC) human drug, contains Benzalkonium Chloride 0.13% and is distributed in 100-wipe boxes under NDC 47682-122-33, alongside other package NDCs including 47682-122, 47682-252, 47682-122-99, 47682-122-71, 47682-252-99, and 47682-252-71. The recalled lots are MN15922 (Exp. Apr 2027), MN31022 (Exp. Oct 2027), and MN27223 (Exp. Aug 2028). For procurement directors and regulatory affairs heads, this Class II classification signifies that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This necessitates immediate action to quarantine affected inventory and assess the integrity of your supply chain for similar topical antiseptic products. The underlying CGMP deviations represent a fundamental failure in quality control, which the FDA consistently targets through enforcement actions, including recalls and Warning Letters. Your business must understand that such deviations, even if leading to a voluntary recall, expose your organization to significant regulatory scrutiny and potential market disruption. Proactive identification and remediation of CGMP non-compliance are paramount to maintaining market access and product integrity.
Commercial Implications of CGMP Non-Compliance for Topical Antiseptic Supply
The recall of Medi-First Antiseptic Wipes by ACME UNITED CORPORATION due to CGMP deviations carries substantial commercial implications for businesses relying on OTC drug products, particularly those containing Benzalkonium Chloride. Supply chain VPs must recognize that a nationwide recall, even if voluntary, can lead to immediate product shortages and impact customer trust. The disruption extends beyond the direct cost of retrieving products; it encompasses potential lost sales, reputational damage, and the significant expense of implementing corrective and preventive actions (CAPA). Regulatory affairs heads should note that CGMP deviations, as the stated reason for this recall, are a primary trigger for FDA enforcement. This incident underscores the critical need for robust quality management systems throughout the entire product lifecycle, from raw material sourcing to finished product distribution. For business development executives, this event highlights the inherent risks in partnerships where quality oversight is lax. Any company involved in the supply chain of these wipes—whether as a contract manufacturer, ingredient supplier, or distributor—could face scrutiny. The product description indicates it is "Manufactured for Medique Products, Fort Meyers, FL," while FDA records also list "Unifirst First Aid Corporation" as a manufacturer. This complex chain emphasizes that responsibility for CGMP compliance is shared, and comprehensive due diligence on all partners is non-negotiable to protect your brand and market position.
ACME UNITED CORPORATION's Market Presence and Product Portfolio in OTC Drugs
ACME UNITED CORPORATION, headquartered in Shelton, CT, operates within the broader consumer and medical products sectors, with its Medi-First Antiseptic Wipes representing a key offering in the human OTC drug category. The active ingredient, Benzalkonium Chloride 0.13%, is a widely used topical antiseptic, essential for wound care and skin sanitization. The nationwide distribution pattern within the United States for these wipes indicates a significant market reach, making the recall impactful across various commercial and healthcare settings. For procurement teams, understanding the recalling firm's role is crucial. While ACME UNITED CORPORATION initiated this recall, the product is explicitly stated as "Manufactured for Medique Products, Fort Meyers, FL," and FDA's open data identifies Unifirst First Aid Corporation as a manufacturer. This multi-entity involvement underscores the complexities of modern pharmaceutical supply chains, where brand owners, contract manufacturers, and distributors all share responsibility for product quality and regulatory compliance. Any business sourcing similar Benzalkonium Chloride-based products, or engaging in private label agreements, must meticulously vet all parties in their supply chain to ensure adherence to FDA CGMP standards. Failure to do so exposes your organization to similar recall risks, impacting product availability and consumer confidence.
Broader Regulatory Landscape: FDA's Continued Scrutiny of Pharmaceutical Quality
The FDA's Class II recall of ACME UNITED CORPORATION's Medi-First Antiseptic Wipes due to CGMP deviations is not an isolated incident but rather indicative of a sustained regulatory focus on pharmaceutical quality and manufacturing integrity. Recent parallel events underscore this trend, demonstrating the FDA's proactive stance across various drug categories. For instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures, published on June 15, 2026. Similarly, Spectra Medical Devices initiated a Class II recall for Lidocaine HCl Injection, also citing sterility assurance deficiencies, on June 10, 2026. Guardian Drug Co. Inc. experienced a nationwide recall for Calcium Carbonate Antacids due to metallic contamination on the same date. These concurrent actions highlight that the FDA is rigorously enforcing CGMP requirements, irrespective of product type or therapeutic area. For regulatory affairs heads and supply chain VPs, this pattern signals that any lapse in manufacturing controls, whether related to sterility, contamination, or general process adherence, will likely trigger significant regulatory consequences. The consistent stream of Class II recalls emphasizes the need for continuous monitoring of FDA enforcement trends and proactive investment in robust quality systems. Your business must anticipate and address potential CGMP vulnerabilities across your entire portfolio to avoid costly recalls, market withdrawals, and the long-term damage to brand reputation that accompanies such regulatory actions.
Navigating Remediation and Mitigating Future Regulatory Risks
Following a Class II recall initiated due to CGMP deviations, such as that undertaken by ACME UNITED CORPORATION for its Benzalkonium Chloride wipes, businesses must prioritize comprehensive remediation and proactive risk mitigation strategies. For regulatory affairs teams, the immediate focus is on ensuring all affected product lots (MN15922, MN31022, MN27223) are effectively removed from distribution and that the root causes of the CGMP deviations are thoroughly investigated. This typically involves a detailed Corrective and Preventive Action (CAPA) plan, which must be robust enough to prevent recurrence. Procurement directors and supply chain VPs should immediately review their supplier qualification programs, especially for critical OTC drug components and finished products. This includes enhanced audit protocols, more stringent quality agreements, and potentially diversifying the supply base for Benzalkonium Chloride and similar active pharmaceutical ingredients to reduce reliance on single sources that may exhibit compliance issues. While specific remediation timelines for ACME UNITED CORPORATION are not publicly detailed in the recall notice, the FDA expects swift and effective action. Failure to adequately address CGMP deficiencies can escalate regulatory actions, potentially leading to further recalls, import alerts for foreign manufacturers, or even a formal Warning Letter. Proactive engagement with regulatory intelligence and continuous improvement in quality systems are essential to safeguard your business from future compliance risks and maintain uninterrupted market supply.